Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Seagen Inc (SGEN)

Seagen Inc (SGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 31,082,830
  • Shares Outstanding, K 184,435
  • Annual Sales, $ 1,574 M
  • Annual Income, $ -674,470 K
  • 60-Month Beta 0.57
  • Price/Sales 19.93
  • Price/Cash Flow N/A
  • Price/Book 10.70
Trade SGEN with:

Options Overview Details

View History
  • Implied Volatility 50.81% ( -3.06%)
  • Historical Volatility 25.96%
  • IV Percentile 70%
  • IV Rank 44.56%
  • IV High 74.87% on 06/06/22
  • IV Low 31.47% on 08/27/21
  • Put/Call Vol Ratio 0.32
  • Today's Volume 4,851
  • Volume Avg (30-Day) 2,898
  • Put/Call OI Ratio 0.61
  • Today's Open Interest 57,731
  • Open Int (30-Day) 43,638

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.90
  • Number of Estimates 10
  • High Estimate -0.62
  • Low Estimate -1.07
  • Prior Year -1.61
  • Growth Rate Est. (year over year) +44.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
164.81 +3.46%
on 08/12/22
181.75 -6.18%
on 07/26/22
-8.19 (-4.58%)
since 07/15/22
3-Month
132.09 +29.09%
on 05/24/22
183.00 -6.82%
on 07/07/22
+27.98 (+19.63%)
since 05/16/22
52-Week
105.43 +61.74%
on 05/09/22
192.79 -11.55%
on 11/08/21
+14.65 (+9.40%)
since 08/16/21

Most Recent Stories

More News
Roche's (RHHBY) sBLA For Polivy Combo Accepted by FDA

Roche's (RHHBY) sBLA seeking approval for the use of Polivy in combination with R-CHP for previously untreated diffuse large B-cell lymphoma in adults has been accepted in the United States.

RHHBY : 41.5700 (-1.68%)
ABBV : 142.55 (+0.18%)
SGEN : 170.52 (+1.18%)
AERI : 11.64 (-0.85%)
Seagen Statement on Outcome of Daiichi Sankyo Arbitration

Seagen Inc. (Nasdaq: SGEN) today issued a statement regarding the outcome of the arbitration with Daiichi Sankyo Co. Ltd. (“Daiichi Sankyo”) relating to the parties’ 2008 collaboration agreement...

SGEN : 170.52 (+1.18%)
Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe

Seagen (SGEN) focuses on improving sales of its marketed drugs approved for different types of cancer indications. Stiff competition in the market remains a woe.

MRK : 90.59 (-0.01%)
SGEN : 170.52 (+1.18%)
TECH : 370.06 (-2.12%)
ATRA : 4.94 (-7.49%)
Seagen's (SGEN) Earnings & Revenues Surpass Estimates in Q2

Seagen (SGEN) reports a narrower-than-expected loss in the second quarter of 2022 while its revenues beat estimates.

RHHBY : 41.5700 (-1.68%)
MRK : 90.59 (-0.01%)
SGEN : 170.52 (+1.18%)
DTIL : 1.99 (-3.40%)
Seagen Inc. (SGEN) Q2 2022 Earnings Call Transcript

SGEN earnings call for the period ending June 30, 2022.

SGEN : 170.52 (+1.18%)
Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates

Seattle Genetics (SGEN) delivered earnings and revenue surprises of 10.98% and 12.26%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

SGEN : 170.52 (+1.18%)
ADMA : 2.40 (-0.41%)
Seagen Reports Second Quarter 2022 Financial Results

Seagen Inc. (Nasdaq:SGEN) reported financial results today for the second quarter ended June 30, 2022. The Company also highlighted PADCEV ® (enfortumab vedotin-ejfv), TUKYSA ® (tucatinib), ADCETRIS...

SGEN : 170.52 (+1.18%)
Drug, Biotech Stocks' Q2 Earnings on Jul 28: MRK, PFE & More

Let's analyze how the five pharma/drug/biotech companies are placed before the quarterly earnings release on Jul 28.

SNY : 44.81 (+2.24%)
ALNY : 228.15 (-1.24%)
PFE : 49.86 (+0.22%)
MRK : 90.59 (-0.01%)
SGEN : 170.52 (+1.18%)
Incyte (INCY) to Report Q2 Earnings: What's in the Cards?

Incyte's (INCY) top line is likely to have been driven by sales of its lead drug, Jakafi, in the second quarter.

NVS : 85.82 (+0.52%)
INCY : 74.96 (-0.43%)
SGEN : 170.52 (+1.18%)
BNTX : 160.37 (-1.30%)
Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer

Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced positive topline results from the phase 1b/2 EV-103 clinical trial...

SGEN : 170.52 (+1.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Seagen, Inc., a biotechnology company, focuses on developing & commercializing therapies targeted for the treatment of cancer. Adcetris, a lead FDA approved marketed product at Seagen, is used for treating Hodgkin lymphoma, certain T-cell lymphomas, other cancers in the U.S., Europe & several countries....

See More

Key Turning Points

3rd Resistance Point 177.60
2nd Resistance Point 175.09
1st Resistance Point 172.81
Last Price 170.52
1st Support Level 168.02
2nd Support Level 165.51
3rd Support Level 163.23

See More

52-Week High 192.79
Last Price 170.52
Fibonacci 61.8% 159.42
Fibonacci 50% 149.11
Fibonacci 38.2% 138.80
52-Week Low 105.43

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar